Prime Medicine (NASDAQ:PRME) Stock Price Up 7.3% – Still a Buy?

Prime Medicine, Inc. (NASDAQ:PRME)’s share price traded up 7.3% on Monday . The stock traded as high as $3.28 and last traded at $3.3050. Approximately 822,799 shares traded hands during trading, a decline of 72% from the average daily volume of 2,925,446 shares. The stock had previously closed at $3.08.

Key Headlines Impacting Prime Medicine

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Prime Medicine is advancing PM577 into a first-in-human clinical study for Wilson disease, a key milestone for the company’s prime-editing platform. The trial provides investors with a potential clinical catalyst and more evidence of progress toward human applications. Prime Medicine Advances First-in-Human Prime Editing Trial in Wilson Disease
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $8.00 price objective, signaling confidence in Prime Medicine’s long-term prospects despite continued operating losses. HC Wainwright Reaffirms Buy Rating for Prime Medicine
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $1.11 from $1.17 and its FY2028 forecast to a loss of $0.92 from $1.01. A smaller projected loss can support sentiment, although the company is still expected to remain unprofitable.
• Neutral Sentiment: Short-interest data showed no reported shares sold short as of August 11, unchanged from the prior period. This offers no meaningful short-squeeze catalyst or bearish signal.
• Negative Sentiment: HC Wainwright modestly reduced several forecasts, including Q2 2027 EPS to a loss of $0.23, Q4 2026 EPS to a loss of $0.32, FY2027 EPS to a loss of $0.91, FY2029 EPS to a loss of $0.96, and FY2030 EPS to a loss of $0.81. These revisions highlight ongoing expectations for significant cash burn and losses.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PRME shares. Wall Street Zen raised Prime Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday. TD Cowen restated a “buy” rating on shares of Prime Medicine in a report on Wednesday, July 8th. Citigroup reaffirmed a “market outperform” rating on shares of Prime Medicine in a research note on Monday, June 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research note on Wednesday, June 3rd. Finally, New Street Research set a $8.00 price target on Prime Medicine in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.53.

Prime Medicine Trading Up 3.5%

The stock’s 50-day moving average is $3.27 and its 200-day moving average is $3.47. The stock has a market cap of $591.30 million, a price-to-earnings ratio of -3.08 and a beta of 2.31.

Prime Medicine (NASDAQ:PRME) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.24) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.24). The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $4.40 million. Prime Medicine had a negative return on equity of 156.84% and a negative net margin of 4,613.11%. On average, equities analysts predict that Prime Medicine, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Prime Medicine

Several large investors have recently added to or reduced their stakes in the stock. Redmile Group LLC bought a new position in Prime Medicine in the 1st quarter worth approximately $5,536,000. ADAR1 Capital Management LLC bought a new position in Prime Medicine during the 1st quarter valued at $6,867,000. UBS Group AG lifted its holdings in Prime Medicine by 700.8% in the 4th quarter. UBS Group AG now owns 2,440,583 shares of the company’s stock valued at $8,469,000 after acquiring an additional 2,135,810 shares during the last quarter. MWG Caph Ltd bought a new stake in shares of Prime Medicine during the 4th quarter worth $6,219,000. Finally, Chelsea Counsel Co. raised its stake in Prime Medicine by 103.7% during the 1st quarter. Chelsea Counsel Co. now owns 462,340 shares of the company’s stock valued at $1,609,000 after purchasing an additional 235,340 shares during the period. 70.37% of the stock is owned by institutional investors and hedge funds.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.